Lazertinib

An irreversible inhibitor of mutant EGFRs

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥1212.00

970.00

- +
10mg

￥2012.00

1610.00

- +
50mg

￥4525.00

3620.00

- +
100mg

￥8525.00

6820.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.

Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib targets both T790M mutation and activating EGFR mutations (EGFRm) while sparing wild type[1].

参考文献:
[1]. Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results.